Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17,009 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reliability of early stage symptoms/clinical findings of osteonecrosis of the jaw: Japanese Osteoporosis Intervention Trial-05 (JOINT-05).
Taguchi A, Tanaka S, Ozaki T, Arai K, Mori S, Ohta H, Hagino H, Tanaka S, Shiraki M, Nakamura T, Soen S; Adequate Treatment of Osteoporosis (A-TOP) Research Group. Taguchi A, et al. Among authors: nakamura t. J Bone Miner Metab. 2023 Nov;41(6):854-864. doi: 10.1007/s00774-023-01466-3. Epub 2023 Oct 28. J Bone Miner Metab. 2023. PMID: 37897672 Clinical Trial.
Comparison of concurrent treatment with vitamin K2 and risedronate compared with treatment with risedronate alone in patients with osteoporosis: Japanese Osteoporosis Intervention Trial-03.
Tanaka S, Miyazaki T, Uemura Y, Miyakawa N, Gorai I, Nakamura T, Fukunaga M, Ohashi Y, Ohta H, Mori S, Hagino H, Hosoi T, Sugimoto T, Itoi E, Orimo H, Shiraki M. Tanaka S, et al. Among authors: nakamura t. J Bone Miner Metab. 2017 Jul;35(4):385-395. doi: 10.1007/s00774-016-0768-5. Epub 2016 Aug 2. J Bone Miner Metab. 2017. PMID: 27484436 Clinical Trial.
Study design of multi-center, open-label randomized controlled, head-to-head trial comparing minodronic acid and raloxifene: Japanese Osteoporosis Intervention Trial (JOINT)-04.
Uemura Y, Tanaka S, Miyazaki T, Tsukiyama M, Sone T, Taguchi A, Soen S, Mori S, Hagino H, Sugimoto T, Fukunaga M, Ohta H, Nakamura T, Orimo H, Shiraki M; Adequate Treatment of Osteoporosis (A-TOP) research group. Uemura Y, et al. Among authors: nakamura t. J Bone Miner Metab. 2019 May;37(3):491-495. doi: 10.1007/s00774-018-0942-z. Epub 2018 Jul 17. J Bone Miner Metab. 2019. PMID: 30019249
Incidence of osteonecrosis of the jaw in Japanese osteoporosis patients taking minodronic acid.
Taguchi A, Uemura Y, Imai T, Tanaka S, Ohta H, Nakamura T, Orimo H, Sugimoto T, Soen S, Shiraki M; Adequate Treatment of Osteoporosis (A-TOP) research group. Taguchi A, et al. Among authors: nakamura t. J Bone Miner Metab. 2019 Sep;37(5):886-892. doi: 10.1007/s00774-019-00990-5. Epub 2019 Feb 4. J Bone Miner Metab. 2019. PMID: 30719580 Clinical Trial.
Influence of symptomatic periodontal disease on changes in skeletal bone density during medication therapy for osteoporosis in postmenopausal women: the Japanese Osteoporosis Intervention Trial (JOINT)-04 and JOINT-05.
Taguchi A, Uemura Y, Tanaka S, Ohta H, Mori S, Hagino H, Shiraki M, Nakamura T, Soen S; Adequate Treatment of Osteoporosis (A-TOP) research group. Taguchi A, et al. Among authors: nakamura t. Arch Osteoporos. 2021 Dec 27;17(1):7. doi: 10.1007/s11657-021-01054-w. Arch Osteoporos. 2021. PMID: 34958402 Clinical Trial.
The sample size required for intervention studies on fracture prevention can be decreased by using a bone resorption marker in the inclusion criteria: prospective study of a subset of the Nagano Cohort, on behalf of the Adequate Treatment of Osteoporosis (A-TOP) Research Group.
Shiraki M, Kuroda T, Nakamura T, Fukunaga M, Hosoi T, Orimo H, Makino K; Adequate Treatment of Osteoporosis (A-TOP) Research Group. Shiraki M, et al. Among authors: nakamura t. J Bone Miner Metab. 2006;24(3):219-25. doi: 10.1007/s00774-005-0675-7. J Bone Miner Metab. 2006. PMID: 16622735
Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen.
Kishimoto H, Fukunaga M, Kushida K, Shiraki M, Itabashi A, Nawata H, Nakamura T, Ohta H, Takaoka K, Ohashi Y; Risedronate Phase III Research Group. Kishimoto H, et al. Among authors: nakamura t. J Bone Miner Metab. 2006;24(5):405-13. doi: 10.1007/s00774-006-0706-z. J Bone Miner Metab. 2006. PMID: 16937274 Clinical Trial.
17,009 results
You have reached the last available page of results. Please see the User Guide for more information.